These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1272 related articles for article (PubMed ID: 19487267)

  • 1. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
    Chen JS; Makovey J; Lassere M; Buchbinder R; March LM
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):464-72. PubMed ID: 24022870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
    J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.
    Bojke L; Epstein D; Craig D; Rodgers M; Woolacott N; Yang H; Sculpher M
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv39-iv47. PubMed ID: 21859705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
    Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
    Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
    Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
    da Silva BS; Bonfá E; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves CR; de Carvalho JF
    Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.